Umifenovir powered by LipodisqTM Sterile Solution Cat. No. #IAX-700-106

Nano-formulated aqueous Umifenorvir (sterile) solution: Ready-to-use!

Umifenovir (Arbidol) is known to have broad-spectrum anti-viral activity and has earlier been approved in China and Russia for treating influenza, SARS, and Lassa viruses. It has been tested in multiple clinical studies as a candidate for use as an anti-COVID19 therapeutic and has been suggested to act at the entry stage and at the post-entry stages by preventing viral attachment and inhibiting the release of virus particles from intracellular vesicles, respectively.
In a recent phase III, clinical study Umifenovir met the primary and secondary endpoint criteria. It has been shown to efficacious, safe and well-tolerated at the tested dosage.

£165.00

Description Features Resources

Synonyms	Ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2(phenylsulfanylmethyl)indole-3-carboxylate, arbidol in a detergent-free nano-formulation made of styrene-maleic acid lipid particles (SMA-Lipid Particles)
Empirical Formula	C₂₂H₂₅BrN₂O₃S . HCl
Concentration	1mg/ml (0.1% w/vol)
Size	1ml
MW	477.4 . 36.5
CAS	131707-23-8
Purity	≥ 95% (HPLC)
Solution pH	7.00-7.50
Solubility	Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq^TM, Malvern Cosmeceutics Ltd., Malvern UK). Avoid the use of buffers with divalent ions such as Ca or Mg or pH <6.5 or >8.0, which can cause particle instability. Unformulated umifenovir is soluble in DMF, DMSO or ethanol.
Formulation	Lipodisq^TM are nanosized lipid-based discoidal particles that can be manufactured to incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids.
Shipping	Ambient
Storage	2-8°C. For long-term storage between -15 and -25°C.
Stability	In its unopened original vial, the product is stable for at least 12 months (-15 and -25°C). Once the glass vial is opened, or if aliquoted into sterile vials under sterile conditions, the product remains stable for an additional 2 months at 2-8°C. Pre-diluted, sterile aqueous solutions are stable for at least 24 hours when stored at 2-8°C.
Appearance	Light yellow coloured clear aqueous solution
Handling	Keep sterile. Avoid skin and eye contact. If the solution is not clear, then pre-warm (~40°C) solution.
Activity	Cell culture tested (human macrophage cell line) (MTT). Recommended starting dilution: 1:200 or higher. Optimal working concentrations depend on the applications and need to be determined. Published procedures using Lipodisq^TM formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimised. Carrier only control: Lipodisq^TMControl Sterile Solution (Cat. No.: IAX-700-100).

Lipodisq^TM Technology

A nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilised by a chaperone molecule annulus.
Internal properties of the phospholipid membrane support the disposition and stabilisation of drug molecule candidates and preserve the native conformation of membrane molecules.
The resulting encapsulated actives are rendered water-soluble and specialised for intra-cellular penetration/delivery via endosomal uptake mechanisms.
Lipodisq^TM solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
For a customizable biodegradable Lipodisq^TM version with a higher concentration of actives or an alternative lipid option, contact Innaxon.

Innaxon as the supplier also welcomes BULK enquiries for this product.

Legal Claim
The Lipodisq^TM technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending.

The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.

Authorized Uses & Restrictions
The purchase of Innaxon product(s) conveys to the buyer the non-transferable right to use the purchased amount of the product and all replicates and derivatives for, internal, non-profit research purposes. The buyer cannot sell, resale or otherwise transfer (a) the product (b) its components or (c) materials made using this product or its components to a third party. The buyer agrees that any activity undertaken with the product and replicates or derivatives will be conducted in compliance with all applicable guidelines, aws, and regulations. The buyer agrees that the product and replicates or derivatives will not be used for any animal or human therapeutic or diagnostic use.

Limited Use License
Purchase does not include any other right or license to use, develop or otherwise exploit our products. Any use of Innaxon products outside of the Authorized Uses requires additional rights from the Licensor.

Download Product Resources

Flyers
Product Data Sheets
Safety Data Sheets